•
ADJ
CT should be offered to p with resected stage II or III NSCLC [I, A] and
can be considered in p with resected stage IB disease and a primary tumour
>4 cm [II, B]. However, pre-existing co-morbidity and postoperative recovery
need to be taken into account in this decision
•
Currently,
ADJ
CT is not recommended in stage IA, with reports of potential
harm, although the number of p in this subgroup was small [II, B]
•
Given the current state of knowledge, targeted agents should not be used
in the
ADJ
setting [II, A]
